Home > Pulmonology > ERS 2020 > Asthma – What's New > IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps

IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps

Presented By
Dr Claire Hopkins, Guy’s and St Thomas Hospital and King’s College London, UK
Conference
ERS 2020
Trial
Phase 3, SYNAPSE
Results from the phase 3 SYNAPSE trial showed that mepolizumab significantly improved nasal polyp score and nasal obstruction. Patients treated with the IL-5 antagonist also had less need for surgery compared with placebo [1]. Chronic rhinosinusitis with nasal polyps (CRSwNP) involves chronic inflammation of the rhinosinal cavities, mostly of type 2 signature, combined with growth of polyps in the nasal airway [2,3]. CRSwNP, entailing symptoms like congestion, facial pain, and hyposmia, also negatively impacts quality of life [2,4,5]. The current standard of care relies on intranasal corticosteroids (CS) with short courses of systemic CS if needed and nasal surgery in case of CS failure [3]. “Unfortunately, the benefit of this is often short-lived, recurrences are common, and many patients suffer from ongoing inadequate control of their disease and symptoms,” said Dr Claire Hopkins (Guy’s and St Thomas Hospital and King’s College London, UK)....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on